Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: evidence from a systematic review

Mahumud, Rashidul Alam ORCID: https://orcid.org/0000-0001-9788-1868 and Alam, Khorshed ORCID: https://orcid.org/0000-0003-2232-0745 and Keramat, Syed Afroz and Ormsby, Gail M. and Dunn, Jeff and Gow, Jeff (2020) Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: evidence from a systematic review. PLoS One, 15 (6):e0233499. pp. 1-15.

[img]
Preview
Text (Published Version)
Rashed_PlosONE.pdf
Available under License Creative Commons Attribution 4.0.

Download (625kB) | Preview

Abstract

Introduction: The World Health Organization (WHO) recommends that human papillomavirus (HPV) vaccination programs are established to be cost-effective before implementation. WHO recommends HPV vaccination for girls aged 9–13 years to tackle the high burden of cervical cancer. This review examined the existing evidence on the cost-effectiveness of the 9-valent HPV vaccine within a global context.

Methods: The literature search covering a period of January 2000 to 31 July 2019 was conducted in PubMed and Scopus bibliographic databases. A combined checklist (i.e., WHO, Drummond and CHEERS) was used to examine the quality of eligible studies. A total of 12 studies were eligible for this review and most of them were conducted in developed countries.

Results: Despite some heterogeneity in approaches to measure cost-effectiveness, ten studies concluded that 9vHPV vaccination was cost-effective and two did not. The addition of adolescent boys into immunisation programs was cost effective when vaccine price and coverage was comparatively low. When vaccination coverage for females was more than 75%, gender neutral HPV vaccination was less cost-effective than vaccination targeting only girls aged 9–18 years. Multi cohort immunization approach was found cost-effective in the age range of 9–14 years. However, the upper age limit at which vaccination was found not cost-effective requires further evaluation. This review identified duration of vaccine protection, time horizon, vaccine price, coverage, healthcare costs, efficacy and discounting rates as the most dominating parameters in determining cost-effectiveness.

Conclusions: These findings have implications in extending HPV immunization programs whether switching to the 9-valent vaccine or the inclusion of adolescent boys’ vaccination or extending the age of vaccination. Further, this review also supports extending vaccination programs to low-resource settings where vaccine prices are competitive, donor funding is available, burden of cervical cancer is high and screening options are limited.


Statistics for USQ ePrint 39551
Statistics for this ePrint Item
Item Type: Article (Commonwealth Reporting Category C)
Refereed: Yes
Item Status: Live Archive
Additional Information: Published version made available under Creative Commons Attribution License 4.0.
Faculty/School / Institute/Centre: Current - Faculty of Business, Education, Law and Arts - School of Commerce (1 July 2013 -)
Faculty/School / Institute/Centre: Current - Institute for Resilient Regions - Centre for Health Research (1 Apr 2020 -)
Date Deposited: 14 Sep 2020 03:13
Last Modified: 30 Sep 2020 03:11
Uncontrolled Keywords: cervical cancer; cost-effective analysis; HPV vaccination; immunisation program; systematic literature review
Fields of Research (2008): 11 Medical and Health Sciences > 1117 Public Health and Health Services > 111799 Public Health and Health Services not elsewhere classified
14 Economics > 1402 Applied Economics > 140208 Health Economics
11 Medical and Health Sciences > 1103 Clinical Sciences > 110311 Medical Genetics (excl. Cancer Genetics)
Socio-Economic Objectives (2008): C Society > 92 Health > 9202 Health and Support Services > 920208 Health Policy Evaluation
Identification Number or DOI: https://doi.org/10.1371/journal.pone.0233499
URI: http://eprints.usq.edu.au/id/eprint/39551

Actions (login required)

View Item Archive Repository Staff Only